哈尔滨医科大学
Harbin Medical University
名字里带这所大学的医院合在一起算,再加上只署大学名称的论文和试验。
只反映研究活动,不代表医疗水平,也不是医疗建议。 使用说明
鼻咽癌
Nasopharyngeal carcinoma2021–2025年中国大陆共有 2,375 篇该病的 PubMed 英文论文,这里牵头了其中 1 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(23.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 1
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.03%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
ClinicalTrials.gov 上的试验4
- Study of DC-CTL Combined With CIK for Advanced Solid Tumor
- A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
- Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)
- The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025年中国大陆共有 2,923 篇该病的 PubMed 英文论文,这里牵头了其中 17 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 17
- 牵头的试验
- 1
- 占中国试验的比例
- 0.2%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Intratumoral and peritumoral heterogeneity based on CT to predict the pathological response after neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma.
- Habitat-aware radiomics and adaptive 2.5D deep learning predict treatment response and long-term survival in ESCC patients undergoing neoadjuvant chemoimmunotherapy.
- Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.
- Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
- Neoadjuvant camrelizumab combined with paclitaxel and nedaplatin for locally advanced esophageal squamous cell carcinoma: a single-arm phase 2 study (cohort study).
ClinicalTrials.gov 上的试验6
- A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
- A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
- A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
肝细胞癌
Hepatocellular carcinoma2021–2025年中国大陆共有 14,765 篇该病的 PubMed 英文论文,这里牵头了其中 165 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(5.5%)相比。
- 牵头的开放试验
- 1
- 牵头的研究论文
- 165
- 牵头的试验
- 1
- 占中国试验的比例
- 0.07%
- 占全球论文的比例
- 0.6%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- An offline to online cognitive behavioral stress management caring program effectively improves psychological pressure, spiritual well-being, and quality of life in postoperative hepatocellular carcinoma patients.
- Comparison of CalliSpheres® microspheres drug-eluting beads and conventional transarterial chemoembolization in hepatocellular carcinoma patients: a randomized controlled trial.
- A Ferroptosis-Related LncRNA Signature Associated with Prognosis, Tumor Immune Environment, and Genome Instability in Hepatocellular Carcinoma.
- Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma.
- An etiology-stratified single-cell atlas identifies FABP4 as a prognostic marker for MASLD-related HCC.
ClinicalTrials.gov 上的试验6
- A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma
- Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
- First in Human Study of SIM0610 in Solid Tumors
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
胃癌
Stomach cancer2021–2025年中国大陆共有 9,782 篇该病的 PubMed 英文论文,这里牵头了其中 125 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(3.9%)相比。
- 牵头的开放试验
- 2
- 牵头的研究论文
- 125
- 牵头的试验
- 6
- 占中国试验的比例
- 0.4%
- 占全球论文的比例
- 0.6%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.
- Effect of sodium-reduced potassium-enriched salt substitutes on stomach cancer: the Salt Substitute and Stroke Study (SSaSS).
- Integrating psychological and dietary care for patients with advanced gastric cancer undergoing chemotherapy: a randomized controlled trial.
- Reminiscence therapy exhibits alleviation of anxiety and improvement of life quality in postoperative gastric cancer patients: A randomized, controlled study.
- Ocular Safety Evaluation of Bemarituzumab in FGFR2b-Overexpressing Gastroesophageal Adenocarcinoma: A 42-Week Follow-Up Study.
ClinicalTrials.gov 上的试验6
- Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
- AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer
- Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
- A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
视网膜母细胞瘤
Retinoblastoma2021–2025年中国大陆共有 301 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(12.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
骨肉瘤
Osteosarcoma2021–2025年中国大陆共有 2,257 篇该病的 PubMed 英文论文,这里牵头了其中 35 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 35
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.7%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Extraskeletal Ewing Sarcoma of the Abdominopelvic Cavity Revealed by 18 F-FDG PET/CT.
- A longitudinal evaluation on 3-year change of anxiety and depression, and their risk factors among parents of childhood and adolescence patients with resectable osteosarcoma: A cohort study.
- Cognitive-behavioral stress management program alleviates anxiety and depression in parents of adolescent patients with osteosarcoma.
- A strategy for challenging tumorous bone regeneration by borosilicate bioactive glass boosting moderate magnetic hyperthermia.
- MARCH8/NSUN6/ROS-mediated DNA damage positive feedback loop regulates cisplatin resistance in osteosarcoma.
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025年中国大陆共有 523 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- Highly enriched exosomal lncRNA OIP5-AS1 regulates gastrointestinal stromal tumor (GIST) resistance to sunitinib through miR-145 and SOX9.
- Application of Computer-Assisted Endoscopic Ultrasonography Based on Texture Features in Differentiating Gastrointestinal Stromal Tumors from Benign Gastric Mesenchymal Tumors.
- N6-methyladenosine-modified microRNA-675 advances the development of gastrointestinal stromal tumors via inhibiting myosin phosphatase targeting protein 1.
ClinicalTrials.gov 上的试验4
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Clinical Evaluation of Genetron D842V PCR Kit in GIST Patients
- A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
- (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST
神经母细胞瘤
Neuroblastoma2021–2025年中国大陆共有 1,132 篇该病的 PubMed 英文论文,这里牵头了其中 7 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 7
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- The wnt/pyruvate kinase, muscle axis plays an essential role in the differentiation of mouse neuroblastoma cells.
- KLF7 promotes neuroblastoma differentiation through the GTPase signaling pathway by upregulating neuroblast differentiation-associated protein AHNAKs and glycerophosphodiesterase GDPD5.
- Single cell analysis reveals the roles and regulatory mechanisms of type-I interferons in Parkinson's disease.
- GDP dissociation inhibitor 1 (GDI1) attenuates β-amyloid-induced neurotoxicity in Alzheimer's diseases.
- REC8 regulates neuroblastoma cell proliferation, migration, invasion, and angiogenesis via STAT3/VEGF signaling.
多发性骨髓瘤
Multiple myeloma2021–2025年中国大陆共有 1,676 篇该病的 PubMed 英文论文,这里牵头了其中 17 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 17
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma.
- Dynamic monitoring of serum ferritin as an adverse prognostic biomarker in patients with multiple myeloma.
- Adhesion of Immunoglobulins to Band3 Promotes Increased Erythrocyte Sedimentation Rate in Multiple Myeloma.
- Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value.
- HNRNPA2B1 Promotes the Progression of Multiple Myeloma via Endoplasmic Reticulum Stress and Autophagy Mediated by CK2 Kinase.
ClinicalTrials.gov 上的试验6
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Risk Stratification and MRD-driven Maintenance for MM After ASCT
- A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
B 细胞急性淋巴细胞白血病
B-cell acute lymphoblastic leukaemia (B-ALL)2021–2025年中国大陆共有 225 篇该病的 PubMed 英文论文,这里牵头了其中 3 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 3
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文3
- First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions.
- Chidamide and venetoclax synergistically regulate the Wnt/β-catenin pathway by MYCN/DKK3 in B-ALL.
- Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
血友病 A
Haemophilia A2021–2025年中国大陆共有 272 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(15.8%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.07%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
视神经脊髓炎谱系疾病
Neuromyelitis optica spectrum disorder (NMOSD)2021–2025年中国大陆共有 485 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(10.5%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
重症肌无力
Myasthenia gravis2021–2025年中国大陆共有 499 篇该病的 PubMed 英文论文,这里牵头了其中 12 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.6%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 12
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.5%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- IMPDH2 facilitates CD4+ T cell activation through AKT/mTOR pathway by upregulating SRPK1 in myasthenia gravis.
- Facile and label-free electrochemical detection of myasthenia gravis-associated AChR antibodies using a laser-induced graphene immunoplatform.
- FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis.
- Construction of ceRNA network mediated by circRNAs screening from microarray and identification of novel biomarkers for myasthenia gravis.
- Impaired cerebral microvascular endothelial cells integrity due to elevated dopamine in myasthenic model.
ClinicalTrials.gov 上的试验1
烟雾病
Moyamoya disease2021–2025年中国大陆共有 356 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(19.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文2
ClinicalTrials.gov 上的试验1
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025年中国大陆共有 989 篇该病的 PubMed 英文论文,这里牵头了其中 17 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(4.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 17
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.
- An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis.
- SCPEP1+ basal cells are associated with the remodeling of oxidative stress signaling networks in idiopathic pulmonary fibrosis.
- YBX1 regulation of alveolar type II epithelial cells in idiopathic pulmonary fibrosis: mechanistic insights and small-molecule drug screening.
- Rosiridin reduces Idiopathic Pulmonary Fibrosis by inhibiting the STAT3/NFκB/SMAD3 signaling pathways.
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025年中国大陆共有 779 篇该病的 PubMed 英文论文,这里牵头了其中 13 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(8.3%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 13
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.2%
这些论文过半是实验室或动物研究。
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Multi-omics framework integrating genetics microbiome and immunity for understanding motor neuron degeneration pathogenesis.
- Integrative genomics and functional immunology reveal Clostridia species as modulators of neuroinflammation in amyotrophic lateral sclerosis.
- DAPK1 induces motor neuron apoptosis in hSOD1G93A-linked amyotrophic lateral sclerosis via regulating the Xiap/JNK pathway.
- Fisetin Attenuates Mutant SOD1 Aggregation in Amyotrophic Lateral Sclerosis via Nrf2-Mediated Autophagy Activation.
- COMM domain containing 4 inhibits hephaestin and ferroportin to enhance neuronal ferroptosis by disturbing the Cu-Fe balance in amyotrophic lateral sclerosis.
白塞病
Behçet disease2021–2025年中国大陆共有 245 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(22.9%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.1%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
IgA 肾病
IgA nephropathy2021–2025年中国大陆共有 736 篇该病的 PubMed 英文论文,这里牵头了其中 6 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(9.4%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 6
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。
牵头的论文5
- Mitochondrial morphological aberrations and redistribution in podocytes with glomerular diseases.
- Epidemiology and risk factors for progression in Chinese patients with IgA nephropathy.
- Effects of disease severity-based nursing intervention on immune function and IFN-γ, IL-6, and TNF-α for children with IgA vasculitis nephritis.
- Identifying functional subtypes of IgA nephropathy based on three machine learning algorithms and WGCNA.
- Identification of miRNA-mRNA network and immune-related gene signatures in IgA nephropathy by integrated bioinformatics analysis.
ClinicalTrials.gov 上的试验1
戈谢病
Gaucher disease2021–2025年中国大陆共有 30 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(6.7%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.4%
先天性巨结肠
Hirschsprung disease2021–2025年中国大陆共有 161 篇该病的 PubMed 英文论文,这里牵头了其中 2 篇(第一或最后作者的第一单位是这里)。
横条是和占比最高的机构(13.0%)相比。
- 牵头的开放试验
- 0
- 牵头的研究论文
- 2
- 牵头的试验
- 0
- 占中国试验的比例
- 0.0%
- 占全球论文的比例
- 0.3%
计入的医院
2021–2025年牵头论文数。有教学关系的省市级医院没有合并进来。